Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Nuclear translocation of Atox1 potentiates activin A-induced cell migration and colony formation in colon cancer.

Jana A, Das A, Krett NL, Guzman G, Thomas A, Mancinelli G, Bauer J, Ushio-Fukai M, Fukai T, Jung B.

PLoS One. 2020 Jan 21;15(1):e0227916. doi: 10.1371/journal.pone.0227916. eCollection 2020.

2.

NFkB is essential for activin-induced colorectal cancer migration via upregulation of PI3K-MDM2 pathway.

Jana A, Krett NL, Guzman G, Khalid A, Ozden O, Staudacher JJ, Bauer J, Baik SH, Carroll T, Yazici C, Jung B.

Oncotarget. 2017 Jun 6;8(23):37377-37393. doi: 10.18632/oncotarget.16343.

3.

Commentary: Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer.

Bauer J, Staudacher JJ, Krett NL, Jung B.

J Rare Dis Res Treat. 2016;1(1):43-45. No abstract available.

4.

Identification of potential glucocorticoid receptor therapeutic targets in multiple myeloma.

Thomas AL, Coarfa C, Qian J, Wilkerson JJ, Rajapakshe K, Krett NL, Gunaratne PH, Rosen ST.

Nucl Recept Signal. 2015 Dec 22;13:e006. doi: 10.1621/nrs.13006. eCollection 2015.

5.

Identification of p38β as a therapeutic target for the treatment of Sézary syndrome.

Bliss-Moreau M, Coarfa C, Gunaratne PH, Guitart J, Krett NL, Rosen ST.

J Invest Dermatol. 2015 Feb;135(2):599-608. doi: 10.1038/jid.2014.367. Epub 2014 Aug 22.

6.

Clinical perspective on chemo-resistance and the role of RNA processing.

Krett NL, Ma S, Rosen ST.

Cancer Treat Res. 2013;158:235-45. doi: 10.1007/978-3-642-31659-3_10.

PMID:
24222361
7.

8-Amino-adenosine activates p53-independent cell death of metastatic breast cancers.

Polotskaia A, Hoffman S, Krett NL, Shanmugam M, Rosen ST, Bargonetti J.

Mol Cancer Ther. 2012 Nov;11(11):2495-504. doi: 10.1158/1535-7163.MCT-12-0085. Epub 2012 Sep 12.

8.

Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms.

McBrayer SK, Yarrington M, Qian J, Feng G, Shanmugam M, Gandhi V, Krett NL, Rosen ST.

PLoS One. 2012;7(7):e41455. doi: 10.1371/journal.pone.0041455. Epub 2012 Jul 27.

9.

Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy.

McBrayer SK, Cheng JC, Singhal S, Krett NL, Rosen ST, Shanmugam M.

Blood. 2012 May 17;119(20):4686-97. doi: 10.1182/blood-2011-09-377846. Epub 2012 Mar 27.

10.

Role for microRNAs in regulating glucocorticoid response and resistance in multiple myeloma.

Tessel MA, Benham AL, Krett NL, Rosen ST, Gunaratne PH.

Horm Cancer. 2011 Jun;2(3):182-9. doi: 10.1007/s12672-011-0072-8.

11.

Inhibition of glycogen synthase kinase-3 increases the cytotoxicity of enzastaurin.

Rovedo MA, Krett NL, Rosen ST.

J Invest Dermatol. 2011 Jul;131(7):1442-9. doi: 10.1038/jid.2011.70. Epub 2011 Apr 7.

12.

8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma.

Dennison JB, Shanmugam M, Ayres ML, Qian J, Krett NL, Medeiros LJ, Neelapu SS, Rosen ST, Gandhi V.

Blood. 2010 Dec 16;116(25):5622-30. doi: 10.1182/blood-2010-05-285866. Epub 2010 Sep 15.

13.

Steroid receptor and microRNA regulation in cancer.

Tessel MA, Krett NL, Rosen ST.

Curr Opin Oncol. 2010 Nov;22(6):592-7. doi: 10.1097/CCO.0b013e32833ea80c. Review.

PMID:
20739888
14.

A collection of bioconductor methods to visualize gene-list annotations.

Feng G, Du P, Krett NL, Tessel M, Rosen S, Kibbe WA, Lin SM.

BMC Res Notes. 2010 Jan 19;3:10. doi: 10.1186/1756-0500-3-10.

15.

Coencapsulation of arsenic- and platinum-based drugs for targeted cancer treatment.

Chen H, Pazicni S, Krett NL, Ahn RW, Penner-Hahn JE, Rosen ST, O'Halloran TV.

Angew Chem Int Ed Engl. 2009;48(49):9295-9. doi: 10.1002/anie.200903655. No abstract available.

16.

Targeting glucose consumption and autophagy in myeloma with the novel nucleoside analogue 8-aminoadenosine.

Shanmugam M, McBrayer SK, Qian J, Raikoff K, Avram MJ, Singhal S, Gandhi V, Schumacker PT, Krett NL, Rosen ST.

J Biol Chem. 2009 Sep 25;284(39):26816-30. doi: 10.1074/jbc.M109.000646. Epub 2009 Jul 31.

17.

Inhibition of ATP synthase by chlorinated adenosine analogue.

Chen LS, Nowak BJ, Ayres ML, Krett NL, Rosen ST, Zhang S, Gandhi V.

Biochem Pharmacol. 2009 Sep 15;78(6):583-91. doi: 10.1016/j.bcp.2009.05.019. Epub 2009 May 27.

18.

Dual regulation of glucocorticoid-induced leucine zipper (GILZ) by the glucocorticoid receptor and the PI3-kinase/AKT pathways in multiple myeloma.

Grugan KD, Ma C, Singhal S, Krett NL, Rosen ST.

J Steroid Biochem Mol Biol. 2008 Jun;110(3-5):244-54. doi: 10.1016/j.jsbmb.2007.11.003. Epub 2008 Apr 20.

19.

Protein kinase A-independent inhibition of proliferation and induction of apoptosis in human thyroid cancer cells by 8-Cl-adenosine.

Robinson-White AJ, Hsiao HP, Leitner WW, Greene E, Bauer A, Krett NL, Nesterova M, Stratakis CA.

J Clin Endocrinol Metab. 2008 Mar;93(3):1020-9. Epub 2007 Dec 11.

20.

Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer drug release.

Chen H, MacDonald RC, Li S, Krett NL, Rosen ST, O'Halloran TV.

J Am Chem Soc. 2006 Oct 18;128(41):13348-9.

PMID:
17031934
21.

Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines.

Rizvi MA, Ghias K, Davies KM, Ma C, Weinberg F, Munshi HG, Krett NL, Rosen ST.

Mol Cancer Ther. 2006 Jul;5(7):1783-9.

22.

The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway.

Querfeld C, Rizvi MA, Kuzel TM, Guitart J, Rademaker A, Sabharwal SS, Krett NL, Rosen ST.

J Invest Dermatol. 2006 Jul;126(7):1641-7. Epub 2006 Apr 27.

24.

8-amino-adenosine is a potential therapeutic agent for multiple myeloma.

Krett NL, Davies KM, Ayres M, Ma C, Nabhan C, Gandhi V, Rosen ST.

Mol Cancer Ther. 2004 Nov;3(11):1411-20.

25.

In vitro assessment of nucleoside analogs in multiple myeloma.

Krett NL, Ayres M, Nabhan C, Ma C, Nowak B, Nawrocki S, Rosen ST, Gandhi V.

Cancer Chemother Pharmacol. 2004 Aug;54(2):113-21. Epub 2004 May 4.

PMID:
15133625
26.

Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells.

Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T, Anderson KC, Rosen ST.

Exp Hematol. 2003 Apr;31(4):271-82. Review.

PMID:
12691914
27.

Caspase activation is required for gemcitabine activity in multiple myeloma cell lines.

Nabhan C, Gajria D, Krett NL, Gandhi V, Ghias K, Rosen ST.

Mol Cancer Ther. 2002 Nov;1(13):1221-7.

28.

Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies.

Greenstein S, Ghias K, Krett NL, Rosen ST.

Clin Cancer Res. 2002 Jun;8(6):1681-94. Review.

29.
30.

8-chloro-cAMP and 8-chloro-adenosine act by the same mechanism in multiple myeloma cells.

Gandhi V, Ayres M, Halgren RG, Krett NL, Newman RA, Rosen ST.

Cancer Res. 2001 Jul 15;61(14):5474-9.

31.

Regulation of protein kinase C delta by estrogen in the MCF-7 human breast cancer cell line.

Shanmugam M, Krett NL, Maizels ET, Cutler RE Jr, Peters CA, Smith LM, O'Brien ML, Park-Sarge OK, Rosen ST, Hunzicker-Dunn M.

Mol Cell Endocrinol. 1999 Feb 25;148(1-2):109-18.

PMID:
10221776
32.

Cyclic adenosine-3',5'-monophosphate-mediated cytotoxicity in steroid sensitive and resistant myeloma.

Krett NL, Zell JL, Halgren RG, Pillay S, Traynor AE, Rosen ST.

Clin Cancer Res. 1997 Oct;3(10):1781-7.

33.

8Cl-cAMP cytotoxicity in both steroid sensitive and insensitive multiple myeloma cell lines is mediated by 8Cl-adenosine.

Halgren RG, Traynor AE, Pillay S, Zell JL, Heller KF, Krett NL, Rosen ST.

Blood. 1998 Oct 15;92(8):2893-8.

PMID:
9763575
34.

Association of PKC delta and active Src in PMA-treated MCF-7 human breast cancer cells.

Shanmugam M, Krett NL, Peters CA, Maizels ET, Murad FM, Kawakatsu H, Rosen ST, Hunzicker-Dunn M.

Oncogene. 1998 Apr 2;16(13):1649-54.

35.

Cell-specific expression of activin and its two binding proteins in the rat decidua: role of alpha 2-macroglobulin and follistatin.

Gu Y, Srivastava RK, Ou J, Krett NL, Mayo KE, Gibori G.

Endocrinology. 1995 Sep;136(9):3815-22.

PMID:
7544272
36.

A variant glucocorticoid receptor messenger RNA is expressed in multiple myeloma patients.

Krett NL, Pillay S, Moalli PA, Greipp PR, Rosen ST.

Cancer Res. 1995 Jul 1;55(13):2727-9.

37.
38.

T47DCO cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance.

Graham ML 2nd, Krett NL, Miller LA, Leslie KK, Gordon DF, Wood WM, Wei LL, Horwitz KB.

Cancer Res. 1990 Oct 1;50(19):6208-17.

39.

Human progesterone receptors: synthesis, structure, and phosphorylation.

Horwitz KB, Sheridan PL, Wei LL, Krett NL.

Prog Clin Biol Res. 1990;322:41-52. Review. No abstract available.

PMID:
2406737
40.

Human progesterone receptor transformation and nuclear down-regulation are independent of phosphorylation.

Sheridan PL, Krett NL, Gordon JA, Horwitz KB.

Mol Endocrinol. 1988 Dec;2(12):1329-42.

PMID:
3063956
41.

Human progesterone A-receptors can be synthesized intracellularly and are biologically functional.

Krett NL, Wei LL, Francis MD, Nordeen SK, Gordon DF, Wood WM, Horwitz KB.

Biochem Biophys Res Commun. 1988 Nov 30;157(1):278-85.

PMID:
3196338
42.

Multiple human progesterone receptor messenger ribonucleic acids and their autoregulation by progestin agonists and antagonists in breast cancer cells.

Wei LL, Krett NL, Francis MD, Gordon DF, Wood WM, O'Malley BW, Horwitz KB.

Mol Endocrinol. 1988 Jan;2(1):62-72.

PMID:
3398843
43.

Immunologic analysis of human breast cancer progesterone receptors. 2. Structure, phosphorylation, and processing.

Wei LL, Sheridan PL, Krett NL, Francis MD, Toft DO, Edwards DP, Horwitz KB.

Biochemistry. 1987 Sep 22;26(19):6262-72.

PMID:
3689774
44.

Mediation of insulin-like growth factor actions by the insulin receptor in H-35 rat hepatoma cells.

Krett NL, Heaton JH, Gelehrter TD.

Endocrinology. 1987 Jan;120(1):401-8.

PMID:
2877866
45.

Regulation of insulin and insulin-like growth factor (IGF) responsiveness by IGFs in rat hepatoma cells.

Heaton JH, Krett NL, Gelehrter TD.

Endocrinology. 1986 Jun;118(6):2555-60.

PMID:
2870917
46.

Madin-Darby canine kidney cells display type I and type II insulin-like growth factor (IGF) receptors.

Krett NL, Heaton JH, Gelehrter TD.

Biochem Biophys Res Commun. 1986 Jan 14;134(1):120-7.

47.

Insulin regulation of insulin-like growth factor action in rat hepatoma cells.

Heaton JH, Krett NL, Alvarez JM, Gelehrter TD, Romanus JA, Rechler MM.

J Biol Chem. 1984 Feb 25;259(4):2396-402.

48.

Insulin resistance in H-35 rat hepatoma cells is mediated by post-receptor mechanisms.

Krett NL, Heaton JH, Gelehrter TD.

Mol Cell Endocrinol. 1983 Sep;32(1):91-100.

49.

Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation.

Furbish FS, Steer CJ, Krett NL, Barranger JA.

Biochim Biophys Acta. 1981 Apr 3;673(4):425-34.

PMID:
6784774
50.

Fucose plays a role in the clearance and uptake of glucocerebrosidase by rat liver cells.

Furbish FS, Krett NL, Barranger JA, Brady RO.

Biochem Biophys Res Commun. 1980 Aug 29;95(4):1768-74. No abstract available.

PMID:
6158326

Supplemental Content

Loading ...
Support Center